Biogen upgraded to Buy from Neutral at Citi. Citi analyst Robyn Karnauskas upgraded Biogen to Buy with a $371 price target after the company announced positive results from an 18-month clinical trial for BAN2401, a drug to treat Alzheimer’s. Shares of Biogen are up 14%, or $41.19, to $340.00 in premarket trading.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.